Start A Thread

Rate Intersect ENT

  • Culture

  • Compensation

  • Opportunity for advancement

  • Realistic plan attainment

×

Salaries

In our drive to help people in the medical sales industry we are gathering salary data. This information will be collated, analyzed and number crunched. Medtechy’s overall goal is to help the medical sales industry make more informed decisions when changing jobs and also keep employers and recruiters honest

Take 30 seconds and let us know your current deal.*

About The Position

Compensation

* We guarantee all data collected is completely anonymous and will only be used for the benefit of future visitors.

×

Medtech[y] Guarantee

COMPANONYMOUS

Our Promise to you - Company & Hospital boards are always anonymous

Manager, FP&A

Menlo Park, CA

Sr. Sales Consultant - Central/North New Jersey

New Jersey

Manager, Regulatory Affairs CMC

Menlo Park, CA

Jobs by Indeed job search

Intersect ENT CONFIDENTIAL TREATMENT ORDER

16 hours ago

Intersect ENT, Inc. submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on June 23, 2014, as amended.

What is XENT trying to hide?


Intersect ENT Insider Selling Part Deux

1 week ago

Face it, Lisa has more shares than she knows what to do with. Ask why they aren't a greater part of your compensation.They will laugh. You should then understand what the E team thinks of the reps. Replaceable.



Earnings Call

2 months ago

I heard the had to lock the sheep up at night in the town he lives in.

Contour

2 months ago

I am sure Binney.


Intersect ENT Earnings $XENT

2 months ago

First Quarter Financial Highlights

  • First quarter 2017 revenue was $20.5 million, a 23% increase over the first quarter 2016.
  • First quarter 2017 gross margin was 86% compared to 81% in the first quarter 2016.

First Quarter Business Highlights

  • In February 2017, the company received approval from the U.S. Food and Drug Administration (FDA) for its PROPEL® Contour steroid releasing sinus implant. PROPEL Contour features an innovative hourglass design that facilitates treatment of patients with chronic…
Intersect ENT Reports First Quarter 2017 Results

Intersect ENT, Inc. , a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2017.

Loading...

'